Jim Keon
CanadapoliticianMale5.5Global Dominance: 0.00%Jim Keon is the president of the Canadian Generic Pharmaceutical Association (CGPA), representing 17 companies in the generics industry. He has been vocal about the delays in Health Canada's approval process for generic drugs, highlighting the impact these delays have on both patients and the financial burden on public and private insurers.
Country presence
Recent news mentions
Jim Keon, president of the Canadian Generic Pharmaceutical Association, said the delays are making it difficult and more expensive for manufacturers to arrange their supply chains.
Health Canada backlog of generic drug applications doubled over past yearCanada· 2026-08-05
Jim Keon, president of the Canadian Generic Pharmaceutical Association, said Canada and the U.S. have spent decades building an integrated pharmaceutical supply chain.
Trump threatens tariffs on generic drugs, complicating Canada’s on-shoring effortsCanada· 2026-07-22
Jim Keon, president of industry group Biosimilars Canada, said the delays are threatening the financial viability of these products.
Health Canada says it is working to reduce backlog of lower-cost biosimilar drug submissionsCanada· 2025-09-05
Jim Keon, president of the CGPA, highlighted the resource shortages and increased submission volume affecting Health Canada's drug approval process.
Health Canada taking longer to approve generic drugs, data showCanada· 2025-08-05
